Centrally acting ACE inhibitor (cACEi) and angiotensin receptor blocker (cARB) use and cognitive dysfunction in patients with SLE.

Chrisanna DobrowolskiMichelle BarracloughJiandong SuMilica TanicKathleen BinghamLesley RuttanDorcas BeatonJoan WitherMaria Carmela TartagliaMary SanoMahta KakvanDennisse BonillaRobin GreenZahi Touma

Published in: Lupus science & medicine (2023)

In a single-centre SLE cohort, cACEi/cARB use was not associated with absence of CD. Many important confounders may have influenced the results of this retrospective study. A randomised trial is required to accurately determine if cACEi/cARB is a potential treatment for SLE-CD.

Keyphrases

systemic lupus erythematosus
angiotensin converting enzyme
disease activity
angiotensin ii
rheumatoid arthritis
nk cells
open label
study protocol
combination therapy
human health
risk assessment
climate change